Detalhe da pesquisa
1.
Abiraterone acetate plus prednisolone for metastatic patients starting hormone therapy: 5-year follow-up results from the STAMPEDE randomised trial (NCT00268476).
Int J Cancer
; 151(3): 422-434, 2022 08 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35411939
2.
Radiotherapy to the prostate for men with metastatic prostate cancer in the UK and Switzerland: Long-term results from the STAMPEDE randomised controlled trial.
PLoS Med
; 19(6): e1003998, 2022 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-35671327
3.
Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial.
Lancet
; 392(10162): 2353-2366, 2018 12 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30355464
4.
Radiotherapy for metastatic prostate cancer-Authors' reply.
Lancet
; 394(10201): 830, 2019 09 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-31498099
5.
Cost-utility analysis of adding abiraterone acetate plus prednisone/prednisolone to long-term hormone therapy in newly diagnosed advanced prostate cancer in England: Lifetime decision model based on STAMPEDE trial data.
PLoS One
; 17(6): e0269192, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-35653395
6.
Quality of Life in Men With Prostate Cancer Randomly Allocated to Receive Docetaxel or Abiraterone in the STAMPEDE Trial.
J Clin Oncol
; 40(8): 825-836, 2022 03 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-34757812
7.
Docetaxel for Nonmetastatic Prostate Cancer: Long-Term Survival Outcomes in the STAMPEDE Randomized Controlled Trial.
JNCI Cancer Spectr
; 6(4)2022 07 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35877084
8.
Association of Bone Metastatic Burden With Survival Benefit From Prostate Radiotherapy in Patients With Newly Diagnosed Metastatic Prostate Cancer: A Secondary Analysis of a Randomized Clinical Trial.
JAMA Oncol
; 7(4): 555-563, 2021 Apr 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33599706
9.
The Automated Bone Scan Index as a Predictor of Response to Prostate Radiotherapy in Men with Newly Diagnosed Metastatic Prostate Cancer: An Exploratory Analysis of STAMPEDE's "M1|RT Comparison".
Eur Urol Oncol
; 3(4): 412-419, 2020 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-32591246
10.
Abiraterone in "High-" and "Low-risk" Metastatic Hormone-sensitive Prostate Cancer.
Eur Urol
; 76(6): 719-728, 2019 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-31447077